← Back to Home

Temab-A receives two FDA breakthrough therapy designations for previously treated colorectal and lung cancers

An antibody-drug conjugate targeting c-Met shows early signs of efficacy in cancers that continue to progress after existing treatments. The two designations can strengthen collaboration on development and review, but results from small trials and pulmonary safety still require more complete evidence.

By SURL BioNews

When cancer continues to progress after multiple rounds of treatment, whether the next drug can delay progression often matters more directly than a novel mechanism of action. AbbVie announced on October 7 that its investigational drug telisotuzumab adizutecan (Temab-A) received two breakthrough therapy designations from the U.S. Food and Drug Administration (FDA), covering certain previously treated patients with colorectal cancer and non-small cell lung cancer, respectively. This development provides regulatory support for two development pathways; it does not mean the drug has been approved for use.

Temab-A is an antibody-drug conjugate (ADC) targeting c-Met. Its antibody recognizes the target and carries a drug payload to tumor cells. The two designations are based primarily on results from the first-in-human trial M21-404 (NCT05029882). However, the colorectal cancer treatment uses a combination regimen, while the lung cancer treatment uses monotherapy, so the patient criteria and evidence for each must be considered separately.

According to AbbVie's announcement and the same press release published by PR Newswire, the colorectal cancer designation covers Temab-A in combination with bevacizumab for patients who have received fluoropyrimidine, irinotecan, oxaliplatin, and anti-VEGF therapy, as well as anti-EGFR therapy when applicable. These criteria focus development on patients who still need new options after multiple existing therapies.

OncLive reported additional data from the phase 1 colorectal cancer cohort: median progression-free survival was 6.8 months among 30 patients who received Temab-A at 2.4 milligrams per kilogram plus bevacizumab, compared with 4.2 months among 20 patients who received trifluridine/tipiracil plus bevacizumab. This measure describes the time before disease progression and cannot be interpreted directly as an extension of overall survival. Both groups were small, and the information currently provided does not fully describe the comparative design or statistical uncertainty. The numerical difference is therefore still insufficient to establish superior efficacy.

The other designation covers Temab-A monotherapy for patients with EGFR wild-type, c-Met-expressing nonsquamous non-small cell lung cancer who have received platinum-containing chemotherapy and anti-PD-(L)1 antibody therapy. OncLive also reported this lung cancer designation. Its scope is limited by histology, molecular characteristics, and prior treatment, and it does not apply to all patients with lung cancer. The information provided on this occasion also lacks sufficient lung cancer efficacy data to assess alongside the colorectal cancer results.

Safety also affects further development. According to OncLive, the incidence of adjudicated interstitial lung disease or pneumonitis among pooled Temab-A trial participants was 5%, including one grade 3 event and no grade 4 or grade 5 events. This percentage comes from a pooled population and cannot be applied directly to any individual cancer type or specific regimen. It nevertheless reminds researchers that pulmonary adverse reactions must continue to be monitored while evaluating antitumor effects.

Breakthrough therapy designation can facilitate close communication between a drug company and the FDA during development, but it does not replace the efficacy and safety evidence required for marketing approval. Temab-A remains an unapproved investigational drug. Larger trials with more comprehensive designs will determine whether these early signals can translate into reliable treatment benefits and which patients may benefit with acceptable risks.

References

  1. AbbVie
  2. OncLive
  3. AbbVie via PR Newswire